In a parallel development, J&J and Legend Biotech are gearing up for an FDA meeting in the United States to discuss the expansion of Carvytki into earlier lines of treatment. Legend Biotech CEO, Ying Huang, anticipates that the meeting will predominantly scrutinize overall survival data, despite ongoing concerns about safety associated with CAR-T therapy, particularly the risk of secondary T-cell cancers.
This focus on overall survival underscores the FDA’s recent emphasis on using it as a composite metric for both efficacy and safety evaluation. While Carvytki has demonstrated promising survival benefits, concerns linger regarding potential toxicities, prompting thorough deliberation during regulatory reviews.
Meanwhile, Bristol Myers Squibb (BMS) faces challenges with their CAR-T therapy, Abecma, which failed to exhibit a significant extension in overall survival compared to standard treatments. The FDA remains cautious about negative trends in overall survival, even if attributed to patient crossover in clinical trials.
J&J and Legend remain optimistic about Carvytki’s potential, concurrently addressing manufacturing challenges to ensure product quality and consistency. However, ongoing safety and efficacy concerns underscore the critical need for comprehensive evaluation and discussion in upcoming regulatory proceedings on both sides of the Atlantic.
https://www.fiercepharma.com/pharma/legend-ceo-offers-preview-high-profile-fda-adcomm-jj-partnered-carvykti
https://www.biospace.com/article/eu-regulators-back-j-and-j-legend-s-carvykti-for-second-line-multiple-myeloma-ahead-of-adcomm/

Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

Plasmids GMP Services

AAV GMP Services
